Recall Alert: Incorrect Pregabalin Dosage Could Be Lethal - Here's What To Do
Drugs prescribed for pain are being pulled from Canadian pharmacies due to possible life-threatening consequences.
JAMP-Pregabalin, a common medication for treating nerve damage-related pain and fibromyalgia, is facing a nationwide recall due to the potential for patients to ingest a higher-than-prescribed dosage. Health Canada has issued a recall notice, stating that some bottles labeled with 50 mg capsules might contain 150 mg pills instead.
The increased dosage could potentially lead to overdose, which may result in serious and even fatal consequences. Such an overdose can manifest as unpredictable mood swings, excessive sleepiness, confusion, depression, agitation, restlessness, and seizures. Moreover, combining high doses of pregabalin with other central nervous system medications might exacerbate heart problems and potentially cause death.
The JAMP-Pregabalin 50 mg capsules under recall carry the Drug Identification Number 02435985, lot number 2305012747, and an expiry date of August 2026. To ensure the safety of patients, it's crucial to verify the contents of the pill bottles.
If you notice any 150 mg capsules (white with "PG" and "150" printed in black), or if you're unsure about the dosage, return the medication to your pharmacy for inspection. Your pharmacist will check the pills and provide a replacement if necessary. In case you can't return the capsules immediately, consult your pharmacist or doctor for guidance.
Should you experience overdose symptoms, seek immediate medical attention. It's also advisable not to discontinue pregabalin without consulting your doctor, as sudden withdrawal could lead to undesirable effects like nausea, diarrhea, and convulsions.
Health Canada is closely monitoring the investigation and recall implementation by the pharmaceutical company. Any side effects or complaints related to this recall should be reported to Health Canada for further action. Pharmacists are also urged to verify the dosage of dispensed medications to safeguard patient safety, and any unusual findings should be reported to both JAMP Pharma and Health Canada.
- The investigation into the JAMP-Pregabalin recall by Health Canada includes cases where some 50 mg capsules might contain 150 mg pills, which is associated with Canada.
- Toronto pharmacists are urged to verify the dosage of dispensed medications to safeguard patient health and wellness, following the news of the JAMP-Pregabalin recall for medical-conditions related to nerve damage.
- If individuals in Toronto notice any 150 mg capsules (white with "PG" and "150" printed in black) or are unsure about the dosage of their JAMP-Pregabalin 50 mg capsules, they should return the medication to their pharmacy for inspection, as part of the health-and-wellness responsibility for their health.
- The science behind the JAMP-Pregabalin recall lies in the potential for patients to ingest a higher-than-prescribed dosage, leading to serious consequences such as overdose, which can manifest in various ways including unpredictable mood swings, excessive sleepiness, and seizures.
